Program
XKH001
A development code. Also written as “XKH001 Injection” and “XKH001Injection”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Dermatitis, Atopic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zhejiang Kanova Biopharmaceutical | 43 open or running | phase 2since Dec 23, 2024 | Dec 23, 2024 | Apr 1, 2027phase 1 · NCT07757659 |
| Beijing Kanova Biopharmaceutical | 20 open or running | phase 2since Jul 24, 2023 | Oct 13, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2021First study: phase 1 study in Healthy AdultsNew to Beijing Kanova BiopharmaceuticalBeijing Kanova Biopharmaceutical · NCT05128409 · 35 enrolled · China
- Jul 24, 2023Phase 2 study in AsthmaBeijing Kanova Biopharmaceutical · NCT05991661 · 24 enrolled · China
- Dec 23, 2024Zhejiang Kanova Biopharmaceutical's first study: phase 1 study in AsthmaNew to Zhejiang Kanova BiopharmaceuticalZhejiang Kanova Biopharmaceutical · NCT07070297 · 12 enrolled · China
- Dec 23, 2024Phase 2 study in Dermatitis, AtopicZhejiang Kanova Biopharmaceutical · NCT07054736 · 120 planned · China
- Mar 31, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveZhejiang Kanova Biopharmaceutical · NCT07519499 · 75 planned
- Jul 28, 2026Phase 1 study in Healthy AdultZhejiang Kanova Biopharmaceutical · NCT07757659 · 2 planned · Australia
Ahead
- Apr 1, 2027Primary completion: phase 1 study in Healthy AdultZhejiang Kanova Biopharmaceutical · NCT07757659
- Dec 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveZhejiang Kanova Biopharmaceutical · NCT07519499
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07757659Healthy Adult · Australia | 1 | Not yet recruiting | Zhejiang Kanova Biopharmaceutical | Apr 1, 2027 | 2 |
| NCT07519499Pulmonary Disease, Chronic Obstructive | 2 | Not yet recruiting | Zhejiang Kanova Biopharmaceutical | Dec 1, 2027 | 75 |
| NCT07070297Asthma · China | 1 | Completed | Zhejiang Kanova Biopharmaceutical | Oct 10, 2024 | 12 |
| NCT07054736Dermatitis, Atopic · China | 2 | Not yet recruiting | Zhejiang Kanova Biopharmaceutical | Oct 1, 2025 | 120 |
| NCT05991661Asthma · China | 2 | Completed | Beijing Kanova Biopharmaceutical | Feb 20, 2024 | 24 |
| NCT05128409Healthy Adults · China | 1 | UNKNOWN | Beijing Kanova Biopharmaceutical | Oct 1, 2024 | 35 |
How it is read
Names in the registry
- “XKH001 Injection”, 5 entries
- “XKH001Injection”, 1 entry
Codes read as this program: XKH001.
Conditions, from the studies’ own filings
- Asthma, 2 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.